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ABSTRACT 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
collagenase clostridium histolyticum is a safe and effective treatment for adult patients with 
Dupuytren’s contracture.  
STUDY DESIGN: Review of two double-blind, placebo-controlled randomized controlled trials 
and one cross-sectional study. All of these studies are published in English between 2009-2013. 
DATA SOURCES: Two double-blind, placebo-controlled randomized controlled trials and one 
cross-sectional study found using PubMed.  
OUTCOMES MEASURED: Each randomized controlled trial measured the ability to meet the 
primary end point and all secondary endpoints, percent decrease in degree of contracture, 
increase in range of motion, patient satisfaction, and recording of adverse events which played a 
significant role in patient quality of life. 
RESULTS: Hurst et al and Gilpin et al showed a significant increase in range of motion and 
decrease in the flexion contracture after the use of collagenase clostridium histolyticum 
compared to the placebo. The NNT for Hurst et al was 2 while the NNT for Gilpin et al was 3. 
There were significantly more adverse effects in the collagenase group than placebo group such 
as contusion and injection site hemorrhage or pain.  Hay et al found surgery was made more 
difficult in 4 out of 15 (26.7%) cases compared to the other 11 out of 15 (73.3%) cases in which 
surgery was not made more difficult.  
CONCLUSIONS: Based on these three studies, collagenase clostridium histolyticum is a safe 
and effective treatment for adults with Dupuytren’s contracture. The studies exhibited significant 
improvement in range of motion and decreasing the flexion contractures involved in 
Dupuytren’s. 
KEY WORDS: Collagenase clostridium histolyticum, Dupuytren’s contracture 
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INTRODUCTION 
 Dupuytren’s contracture is a disorder in which collagen is produced in excess amounts 
and is deposited in the palmar aspect of the hands surrounding the tendons. With time, thick 
cords form and lengthen down the hand which leads to flexion contractures. These flexion 
contractures greatly limit the hand’s ability to function.1 This paper evaluates two double-blind, 
placebo-controlled trials and a cross-sectional study comparing the safety and efficacy of 
collagenase clostridium histolyticum in adult patients with Dupuytren’s contracture. 
 Dupuytren’s contracture is relevant to the physician assistant profession and to patients 
because of its incidence, cost, and effect on a patient’s quality of life. The incidence of 
Dupuytren’s contracture is 4% in the United States2 and 3-6% of whites globally.1 The cost for 
the fasciectomy surgical procedure which has historically been the standard of care treatment for 
Dupuytren’s contracture is $2102.56 while the cost for the collagenase clostridium histolyticum 
injection is $1418.04, which makes the injection form of treatment cost 33% less than the 
fasciectomy.
3
  
While the underlying etiology of Dupuytren’s contracture is unknown, genetics are 
thought to play a role since a positive family history is common in patients with Dupuytren’s 
contracture.
2
 Recurrence is a common process with Dupuytren’s contracture no matter the 
treatment. Recurrence usually occurs as a slow process over a few years.  
There are different treatment modalities for Dupuytren’s contracture. Dupuytren’s 
contracture can be treated via needle aponeurotomy, open fasciectomy/fasciotomy surgical 
procedures, or via collagenase clostridium histolyticum injection.
4
 Currently, the standard of care 
for Dupuytren’s contracture is an open fasciectomy. Collagenase clostridium histolyticum is 
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being proposed as a new treatment because it is less invasive, carries less risk than the surgical 
option, and is more cost-effective than an open fasciectomy.  
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not collagenase 
clostridium histolyticum is a safe and effective treatment for adult patients with Dupuytren’s 
contracture. 
METHODS 
The population in the 2 randomized, double-blind, placebo-controlled trials and 1 cross-
sectional article utilized in this review includes adult patients with Dupuytren’s contracture. The 
intervention for the treatment group was 0.58 mg collagenase clostridium histolyticum injection. 
The comparison used in patients who were in the control group was a placebo injection of 10mM 
tris plus 60mM sucrose. The outcomes measured were the safety and efficacy of collagenase 
clostridium histolyticum which were measured by the ability to meet the primary and all 
secondary endpoints, increase in range of motion, recording of adverse events, and surveys on 
the distortion of anatomy completed by surgeons who performed open fasciectomy procedures 
on recurrent Dupuytren’s cords after previously receiving collagenase clostridium histolyticum. 
All of these have a significant effect on the quality of life for patients. 
Keywords used in searches for these articles on PubMed were Dupuytren’s disease, 
clostridial collagenase, Dupuytren’s contracture, collagenase clostridium histolyticum, and 
Dupuytren’s. The articles chosen were published in English. Inclusion criteria used for selection 
of the patients in these studies were healthy males and female over age 18 with Dupuytren’s 
contracture, women who were either postmenopausal or used contraception, 
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metacarpophalyngeal (MCP) contractures between 20ᵒ and 100ᵒ or proximal interphalangeal 
(PIP) contractures between 20ᵒ and 80ᵒ, and the inability to place affected finger and palm flat on 
a table at the same time. Exclusion criteria included women who were breastfeeding or pregnant, 
people with bleeding disorders, recent stroke, previous treatment to the affected digit within 90 
days, use of a tetracycline derivative within 14 days, anticoagulant within 7 days, allergy to 
collagenase, or anyone with chronic muscle, neurologic, or neuromuscular disorder that affects 
the hands. The author searched the articles via PubMed and selected them based on their 
relevance to the safety and efficacy of collagenase clostridium histolyticum and if the articles 
included outcomes that matter to patients. The statistics reported or used in the articles were 
relative benefit increase (RBI), absolute benefit increase (ABI), numbers needed to treat (NNT), 
confidence interval (CI), and p-values. Table 1 displays the above mentioned information. 
Table 1- Demographics & Characteristics of included studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
criteria 
Exclusion criteria W/D Interventions 
Hurst 
1
 
(2009) 
Double 
blind 
RCT 
308 62.7 
+/- 9.5 
Patients over 
18, women 
who were 
either 
postmenopaus
al or used 
contraception, 
MCP 
contractures 
between 20ᵒ 
and 100ᵒ or 
PIP 
contractures 
between 20ᵒ 
and 80ᵒ, 
inability to 
put finger and 
palm flat on 
table at same 
time 
Pregnant or 
breastfeeding women, 
bleeding disorders, 
recent stroke, 
previous treatment 
within 90 days of 
affected finger, use of 
tetracycline 
derivative within 14 
days of study, use of 
anticoagulant within 
7 days of study, 
allergy to 
collagenase, patients 
with chronic muscle, 
neurologic, or 
neuromuscular 
disease to hands 
2 0.58 mg 
collagenase 
clostridium 
histolyticum 
plus 0.25 mL 
sterile diluent 
for MCP 
joints or 0.20 
mL sterile 
diluent for 
PIP joints 
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Gilpin
4
 
(2010) 
Double 
blind 
RCT 
66 63.8 
+/- 9.0 
Patients over 
18, women 
who were 
either 
postmenopaus
al or used 
contraception, 
MCP 
contractures 
between 20ᵒ 
and 100ᵒ or 
PIP 
contractures 
between 20ᵒ 
and 80ᵒ, 
inability to 
put finger and 
palm flat on 
table at same 
time 
Pregnant or 
breastfeeding women, 
bleeding disorders, 
recent stroke, 
previous treatment 
within 90 days of 
affected finger, use of 
tetracycline 
derivative within 14 
days of study, use of 
anticoagulant within 
7 days of study, 
allergy to 
collagenase, patients 
with chronic muscle, 
neurologic, or 
neuromuscular 
disease to hands 
2 0.58 mg 
collagenase 
clostridium 
histolyticum 
+ lyophilized 
tris + sucrose 
Hay
5
 
(2013) 
Cross 
sectional 
15 n/a Adult patients 
with 
Dupuytren’s 
contracture 
recurrence 
after a 
previous 
collagenase 
clostridium 
histolyticum 
injection 
Adult patients with 
Dupuytren’s 
contracture with no 
prior treatment with 
collagenase 
clostridium 
histolyticum 
0 n/a 
 
OUTCOMES MEASURED 
 The outcomes measured include ability to meet the primary end point and all secondary 
endpoints, percent decrease in degree of contracture, increase in range of motion, and recording 
of adverse events. The primary end point was a reduction of the joint contracture to 0-5ᵒ of full 
extension by day 30 post-injection. Secondary end points were two different times used to 
compare recurrence of the contracture. These two times were 30 days after the first injection and 
30 days after the last injection.
1,4 
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Changes in range of motion were measured by using the finger goniometry technique. 
These angles were measured during screening prior to starting the treatments, during treatment, 
and 90 days after treatment. To monitor safety and adverse events, patients were monitored for 
60 minutes after the injection. In addition, their vital signs were monitored before injection, for 
60 minutes following injection, on days 1, 7, 30, and 90. Blood and urine samples were obtained 
at screening, 30 and 90 days after injection.
1
 
RESULTS 
 Hurst et al
1
 and Gilpin et al
4
, both double-blind placebo-controlled randomized controlled 
trials evaluated the safety and efficacy of collagenase clostridium histolyticum on Dupuytren’s 
contractures by comparing experimental groups to control groups. The experimental groups 
received the collagenase clostridium histolyticum injection into the affected anatomy whereas 
the control groups received a placebo injection into the affected anatomy.  
Hay et al
5
, a cross sectional study examined the distortion of anatomy in the area 
collagenase clostridium histolyticum was injected in patients who had recurrence of Dupuytren’s 
contracture after receiving the injection. The study gathered information by surveying surgeons 
performing the open fasciectomy on these patients who received the collagenase clostridium 
histolyticum injection previously.  
Table 2. Efficacy of collagenase clostridium histolyticum in the treatment of Dupuytren’s 
contracture 
Study Relative 
Benefit 
Increase (RBI) 
Absolute 
Benefit 
Increase (ABI) 
Number 
Needed to 
Treat (NNT) 
P-value Confidence 
Interval 
(CI) 
Hurst
1
 (2009) 8.41 0.572 2 patients <0.001 95% 
(primary 
end point) 
99% 
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(secondary 
end point) 
Gilpin
4 
(2010) 8.25 0.396 3 patients <0.001 n/a 
Hay
5
 (2013) n/a n/a n/a n/a n/a 
 
Table 3. Comparison of MCP and PIP range of motion (ROM) before and after treatment  
Study MCP ROM 
before treatment 
MCP ROM after 
treatment 
PIP ROM before 
treatment 
PIP ROM after 
treatment 
Hurst
1
 (2009) 43ᵒ 84ᵒ 46ᵒ 75ᵒ 
Gilpin
4 
(2010) 40ᵒ 80ᵒ 41ᵒ 73ᵒ 
Hay
5
 (2013) n/a n/a n/a n/a 
 
Hurst et al
1
 evaluated the efficacy in numerous ways. The collagenase group met the 
primary and secondary end points significantly more than the placebo group (p<0.002). In 
addition, contractures were returned to 0-5ᵒ of full extension in 64% of joints in the collagenase 
group compared to 6.8% in the placebo group. Most of the joints in the collagenase group that 
did not meet the primary or secondary end points did not receive all of the injections. The most 
common reason for this was that there was no palpable cord present. Table 3 illustrates the 
change in range of motion before and after treatment with collagenase clostridium histolyticum. 
A median of 56 days was required to attain the primary end point. Out of all the joints that met 
the primary end point, none had recurrence by day 90.
1
 
Additionally, 96.6% of patients who received the collagenase injection experienced at 
least 1 adverse effect compared to 21.2% in the placebo group. Significantly more injection and 
manipulation-related events  such as contusion, injection site hemorrhage, injection site pain, 
pain in upper extremity, tenderness, ecchymosis, injection site swelling, pruritis, skin laceration, 
LN enlargement and pain on palpation, lymphadenopathy, erythema, blister, injection-site 
pruritis and axillary pain were noted in the collagenase group ( p< or equal to 0.02).
 
Most were 
mild to moderate in severity and resolved without intervention within a median of 10 days. Of 
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note, 20 patients in experimental group and 2 in placebo group experienced severe reactions such 
as peripheral edema, injection site pain or hemorrhage, contusion, tenderness, or tendon rupture. 
There were no deaths or nerve injuries reported.
1
 Therefore, the NNT was calculated as 2 (Table 
2), which means that for every 2 patients treated with collagenase clostridium histolyticum, one 
more patient will have improvement of their condition compared to the control. 
In the 12 month double-blind phase of Gilpin et al
4
, the collagenase-injected group 
experienced significantly reduced contractures compared to the placebo group (44.4% reduction 
vs 4.8% reduction, p<0.001). In the experimental group, it took a mean of 57 days to reach the 
primary end point and a mean of 1.5 injections. Most of the joints in the collagenase group that 
did not meet the primary end point did not receive 3 injections into the affected cord, most often 
because there was “no palpable cord to inject.”4 When analyzing data from the entire 12 month 
study, 134 Dupuytren’s cords were injected with collagenase. From those, 62 were MCP joint 
cords and 72 were PIP joint cords. Additionally, 42 of the 62 (67.7%) MCP joints and 26 of 72 
(36.1%) PIP joints had a reduction in contracture after the last injection.
4
 
Recurrence was defined in the study as an increase in joint contracture to 20ᵒ or greater in 
the presence of a palpable cord at any time during the study in joints that had a reduction in 
contracture to 0ᵒ to 5ᵒ of normal. No joint met these criteria by the end of the study, which lasted 
for 12 months.
4
 
Gilpin et al
4
 measured safety by noting the adverse events experienced by the patients. 
All (100%) of the patients who got the collagenase injection reported at least one adverse effect 
compared to 8 out of 21 (38%) patients in the placebo group. Patients who were injected with 
collagenase had significantly higher rates of edema, contusion, extremity pain, injection site pain 
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or hemorrhage, and lymphadenopathy compared to the placebo group (p<0.05). Most adverse 
effects were mild or moderate and resolved within a median of 8-10 days. One serious adverse 
effect experienced by a patient was a flexion pulley rupture. No arterial, nerve, or tendon injuries 
were reported during the 12 month study.
4
 The NNT was calculated as 3 (Table 2) which means 
that for every 3 patients treated with collagenase clostridium histolyticum, one more patient will 
have improvement in their condition compared to the control. 
 Hay et al presented the results as continuous data in the form of 5 grades which 
represented the level of difficulty in performing open surgical procedures on patients who 
received the collagenase clostridium histolyticum injection previously. Grade 1 was defined as 
easier than a primary operation. Grade 2 was equivalent to a primary operation in difficulty. 
Grade 3 was harder than a primary operation, grade 4 was equivalent to a revision operation, and 
grade 5 was harder than a revision operation. Out of 15 cases, 9 were rated as grades 1 or 2 of 
difficulty. Additionally, 2 cases were grade 4 difficulty and 4 cases were rated as grade 5 
difficulty.
5
 
 For ease of understanding, these results were converted to dichotomous data in this 
review. The data was converted into the following two groups: surgery was made more difficult 
as a result of the collagenase clostridium histolyticum and surgery was not made more difficult 
as a result of the collagenase clostridium histolyticum injection. Surgery was made more difficult 
in 4 out of 15 (26.7%) cases compared to the other 11 out of 15 (73.3%) cases in which surgery 
was not made more difficult from the collagenase injection. The respondents described the 
findings of anatomy in the 4 cases which were more difficult. The anatomy was described as 
“thick” and “hard” scars that made dissecting difficult.5 
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DISCUSSION 
Collagenase clostridium histolyticum is FDA approved for the treatment of Dupuytren’s 
contracture and for men age 18 and older, Peyronie’s disease.6 Often any new product requires 
an extended period of time for health care providers to integrate it into their practice. 
Subsequently, it is much easier to find a healthcare provider who uses collagenase clostridium 
histolyticum in an urban setting compared to a rural area due to the prevalence of physicians. 
This is improving with time. In addition, while collagenase clostridium histolyticum is more 
affordable than the open fasciectomy, it is still expensive if insurance fails to cover it or if a 
patient is uninsured. This is another potential barrier to care. The sponsor of clostridium 
collagenase histolyticum, Auxilium Pharmaceuticals, offers a co-pay reimbursement program 
and a patient assistance program which may help deflect some of the cost if a patient qualifies. It 
is important to note that collagenase clostridium histolyticum is contraindicated in patients who 
have a history of hypersensitivity to collagenase. Additionally, since these studies were 
performed on adults age 18 and over, it is not known if collagenase clostridium histolyticum is 
safe to use in patients under age 18.
6
 
Gilpin et al
4
 highlights the importance of continued follow-up over the next several years 
with patients in the study to monitor the affected cord. Hurst et al
1
 expressed the importance in 
assessing patient compliance with wearing custom fitted splints after the injection every night for 
up to 4 months. Hay et al
5
 noted the importance of evaluating more patients but explained there 
are a limited number of patients who have undergone surgery after receiving collagenase 
injections which limited their study. Hay et al
5
 also noted the potential of subjectivity in the 
responses from the healthcare providers they surveyed as well as the subjectivity of noting 
distortion of anatomy during the surgeries performed.  
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CONCLUSION 
Based on this systematic review of the chosen studies, collagenase clostridium 
histolyticum is a safe and effective treatment for adult patients with Dupuytren’s contracture. 
The data in these studies represents the efficacy and safety of collagenase clostridium 
histolyticum. Future areas of study in long-term follow up would be beneficial to monitor 
continued patient satisfaction and recurrence. Additionally, it would be beneficial to include 
larger sample sizes in future studies.  
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